# Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

- Source: PR Newswire M&A
- Published: 2026-10-29T20:02:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/biohaven-reports-recent-business-developments-and-third-quarter-2026-financial-results-302924206.html
- Canonical: https://groundlevelnews.com/story/biohaven-reports-recent-business-developments-and-third-quarter-2026-f-2f8300/

The US Food and Drug Administration (FDA) accepted new drug application resubmission for Vyglxia (troriluzole) in spinocerebeller ataxia (SCA), user fee goal date 1Q27. Announced exclusive global license with SK Biopharmaceuticals Co., Ltd. for Kv7 ion channel platform, including opakalim...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._